Jean-Guillaume LAFAY - Chief Executive Officer (CEO) & Co-founder of Mablink Bioscience

Mr. Jean-Guillaume Lafay holds a Master’s degree in Medicinal Organic Chemistry (University of Lyon, France). He has a strong entrepreneurship background and a great experience in management. He previously held the position of Director of Sales and Marketing for a French biotechnology company. In 2018 he co-founded Mablink Bioscience, which he now runs.

Edouard Leroy, C.B.D.O.

Edouard LEROY – Chief Business Development Officer (CBDO)

Mr. Edouard Leroy holds a master’s degree in « Research in Physiology and Physiopathology ». He began his career at Servier in a business intelligence team. He then joined a biotech company in the field of antibodies development. He continued his career as a sales manager for a global provider in Life Science solutions, where he was accountable for France and Benelux areas. Overall, Edouard has developed a professional network covering in particular the main players in the pharmaceutical and biotechnology industries in Europe and North America.

Dr. Warren VIRICEL - Chief Scientific Officer (CSO) & Co-founder of Mablink Bioscience

Dr. Warren Viricel holds a PharmD and a PhD in “Biomedical Engineering”, respectively from the University of Lyon (France) and the University of Montréal (Canada). Upon his return to France in 2016 he founded Lina Therapeutics and developed the proprietary “hydrophilic drug-linker ADC platform”, involving Pr. Joseph and Pr. Dumontet in the process. The technology was ultimately entirely transferred to Mablink in 2018. His expertise in medicinal organic chemistry, bioconjugation, pharmacology and antibody-drug conjugates makes him a key asset to the company.

Valerie Attuil-Audenis, C.O.O.

Dr Valérie ATTUIL-AUDENIS – Chief Operating Officer (COO)

Dr Valérie Attuil-Audenis holds a PhD in immunology from the University of Lyon (France). She has worked 10 years in academia, specializing virology and immunology. With her strong background, she joined in 2010, a biotech company developing polyclonal and monoclonal antibodies, where she worked for 8 years as a product manager. She was liaising between R&D, production and marketing. She was also in charge of developing new projects and monitoring customer projects for the development of new antibodies.